Panacea Index Logo

Command Palette

Search for a command to run...

Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.

Atherosclerosis
September 1, 2016
Gerald F Watts et al. (5 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to determine whether a prudent diet combined with cholestyramine could reduce coronary atherosclerosis progression in men with familial hypercholesterolaemia (FH).

Results Summary

The study found that the diet plus cholestyramine significantly reduced LDL cholesterol by 35% and slowed coronary atherosclerosis progression compared to usual care, with fewer patients showing progression and some showing regression.

Population

26 men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD).

Effective Dosage

Cholestyramine 8 g twice daily (diet details not specified).

Duration

39 months.

Interactions

None mentioned.

Extracted Claims (13)
InterventionDirectionEndpointPopulationDosageImpactClaim #
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
coronary atherosclerosis
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
-
decrease
#1
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
mean plasma LDL-Ch concentration
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
35%
fell
#2
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
mean plasma LDL-Ch concentration
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
3.78 (SD 0.98) mmol/L compared with UC at 4.89 (1.04)
remained significantly lower
#3
usual care
decrease
MAWS (mean absolute width of segments)
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
0.252 (SEM 0.072) mm
decreased
#4
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
MAWS (mean absolute width of segments)
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
0.001 (0.065) mm
decreased
#5
usual care
decrease
MinAWS (minimum absolute width of segments)
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
0.290 (0.087) mm
reductions
#6
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
MinAWS (minimum absolute width of segments)
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
0.013 (0.058) mm
reductions
#7
usual care
increase
coronary atherosclerosis
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
7 patients (50%)
progression was observed
#8
fat-modified diet plus cholestyramine (8 g twice daily)
increase
coronary atherosclerosis
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
3 patients (25%)
progression was observed
#9
usual care
decrease
coronary atherosclerosis
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
no patients (0%)
regression
#10
fat-modified diet plus cholestyramine (8 g twice daily)
decrease
coronary atherosclerosis
men with familial hypercholesterolaemia (FH) and coronary artery disease (CAD)
3 patients (25%)
regression
#11
prudent diet and cholestyramine
increase
course of coronary atherosclerosis
men with phenotypic FH
-
improve
#12
prudent diet and cholestyramine
decrease
LDL-Ch
men with phenotypic FH
-
sustained reductions
#13
Abstract

BACKGROUND AND AIMS: Familial hypercholesterolaemia (FH) profoundly increases the risk of coronary artery disease (CAD). We investigated whether diet and a bile-acid sequestrant decrease coronary atherosclerosis in patients with FH. METHODS: We identified 26 men with FH and CAD, participating in the St Thomas' Atherosclerosis Regression Study, who had been randomized to receive a fat-modified diet plus cholestyramine (8 g twice daily) (DC, n = 12) or usual care (UC, n = 14), and investigated the relative effects of these treatments on the angiographic progression of coronary atherosclerosis over 39 months. FH was defined as probable/definite according to Dutch Lipid Clinic Network criteria; mean FH score was 8.7 (range 6-15) and mean baseline low-density lipoprotein cholesterol (LDL-Ch) concentration was 5.4 (SD 1.4) mmol/L. Coronary atherosclerosis was assessed by serial quantitative angiography as the global changes in mean and minimum absolute width of segments (MAWS and MinAWS, respectively). RESULTS: Mean plasma LDL-Ch concentration fell by 35% with DC and remained significantly (p < 0.001) lower during the trial at 3.78 (SD 0.98) mmol/L compared with UC at 4.89 (1.04). MAWS decreased by 0.252 (SEM 0.072) mm in the UC group and by 0.001 (0.065) mm in the DC group (p = 0.007), with corresponding reductions in MinAWS of 0.290 (0.087) mm and 0.013 (0.058) mm (p = 0.009); these changes were significant after adjusting for baseline variables, including coronary luminal dimensions and lipoprotein(a). Progression was observed in 7 patients (50%) on UC and 3 (25%) on DC (p = 0.19), with regression in no patients (0%) and 3 patients (25%) (p < 0.05), respectively. CONCLUSIONS: This investigation, carried out in the pre-statin era, demonstrates that a prudent diet and cholestyramine could improve the course of coronary atherosclerosis in men with phenotypic FH through sustained reductions in LDL-Ch.

Medical Subject Headings (MeSH)
AdultAgedAngiographyAnticholesteremic AgentsCholesterol, LDLCholestyramine ResinCoronary Artery DiseaseData Interpretation, StatisticalDietDisease ProgressionHumansHyperlipoproteinemia Type IIIncidenceMaleMiddle AgedPhenotypeSeverity of Illness IndexTreatment Outcome
Study Links
Quality Scores
SafetyNot Assessed
Efficacy85/10
Quality75/10
Citation Metrics
Total Citations10
Citations/Year1.1
Relative Citation Ratio0.28
NIH Percentile14.5%
Research Impact Scores
APT Score0.50
Weight Score1.70
Normalized Score0.69
Related Supplements
Angiographic progression of coronary atherosclerosis in pati... | Panacea Index